STOCK TITAN

Compugen - CGEN STOCK NEWS

Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.

Overview of Compugen

Compugen Ltd. (symbol: CGEN) is a clinical-stage cancer immunotherapy company that stands at the intersection of advanced computational discovery and therapeutic development. Leveraging its proprietary AI/ML-powered predictive platform, Unigen™, Compugen identifies novel drug targets and biological pathways that drive innovative treatment solutions for complex cancers. The company is deeply engaged in harnessing computational biology to advance next-generation immunotherapies across critical areas such as immuno-oncology, therapeutic proteins, and monoclonal antibodies. Keywords like "computational discovery", "cancer immunotherapy", and "immuno-oncology" anchor its narrative from the very start, ensuring clarity and effectiveness in addressing investor and research queries.

Innovative Computational Discovery and Research Platform

At the heart of Compugen's operations is its cutting-edge computational discovery platform, Unigen™. This platform integrates a wealth of proprietary scientific understanding with predictive algorithms and machine learning systems to simulate and analyze complex biological interactions. Such an approach allows the company to rapidly generate robust hypotheses regarding potential drug targets, reducing the traditional cycle time associated with therapeutic discovery. By enabling high-throughput in silico screening and validation, Compugen is able to efficiently prioritize candidates for subsequent clinical development.

Therapeutic Pipeline and Product Candidates

Compugen has developed a diversified pipeline with multiple proprietary product candidates that are advancing in various stages of clinical development:

  • COM701: A potential first-in-class antibody targeting PVRIG, aimed at modulating immune checkpoints to enhance anti-tumor responses.
  • COM902: A potential best-in-class reduced Fc antibody targeting TIGIT, designed to work synergistically with other immune checkpoint inhibitors.
  • COM503 (GS-0321): A high affinity, potential first-in-class antibody that targets the IL-18 binding protein. By inhibiting this natural regulatory mechanism, the product candidate aims to boost intrinsic anti-tumor immunity by liberating IL-18 activity within the tumor microenvironment.

In addition to these core assets, Compugen participates in clinical-stage collaborative programs, including a PD-1/TIGIT bispecific antibody, where its technology has enriched the genomic and immune profiling of tumors. By combining multiple mechanisms of action, the company aims to address the challenges of immune resistance and provide alternative therapeutic strategies for solid tumors.

Collaborations and Strategic Partnerships

Compugen’s business model is significantly bolstered by its strategic collaborations and licensing partnerships. Well-established alliances with major players such as AstraZeneca and Gilead allow Compugen to extend the reach of its discoveries into critical development phases. These collaborations facilitate the sharing of technological insights and ensure that its promising molecules can benefit from the extensive clinical and regulatory experience of its partners. Typically, such agreements include milestone payments and revenue sharing mechanisms that provide financial stability and reinforce the company’s competitive positioning in the high-stakes field of therapeutic development.

Integrated Business Model and Market Position

Positioned within a rapidly evolving biopharmaceutical landscape, Compugen exemplifies a blend of computational innovation and translational science. Its operations are structured around the key pillars of target discovery, clinical validation, and strategic collaboration. This integrated approach not only minimizes the typical risks associated with early-stage drug development but also enhances the potential for generating impactful clinical data. Moreover, Compugen’s clear focus on addressing unmet needs in immunology and oncology illustrates its commitment to advancing therapeutic options for patients with challenging cancers.

Competitive Differentiation and Industry Expertise

Compugen differentiates itself through its unique blend of advanced computational technologies and deep biological insight. By harnessing the power of AI and machine learning, the company rapidly decodes complex tumor biology, thus offering a competitive edge over traditional wet-lab discovery methods. Its rigorous scientific methodology, combined with ongoing validation in peer-reviewed research and clinical trial data, underscores its role as a trusted innovator in the therapeutic discovery space. The attribute of computational precision in target identification is not only novel but also adds a level of efficiency in pipeline development, positioning Compugen uniquely among its peers within the biopharmaceutical industry.

Scientific Publications and Thought Leadership

Compugen routinely contributes to the broader scientific discourse by publishing peer-reviewed studies that detail its computational target discovery methods and preclinical data. These publications, presented at key scientific conferences and in leading industry journals, bolster the company’s credibility and demonstrate its commitment to transparency and scientific rigor. By continuously adding to the collective knowledge in immuno-oncology and computational biology, Compugen reinforces its authority as a pioneer in developing innovative cancer treatments.

Investor Considerations and Operational Impact

For investors and market analysts, Compugen represents a well-structured business model that effectively marries scientific innovation with strategic commercialization pathways. Its revenue streams are primarily driven by collaborative agreements and milestone-based payments that reduce dependency on internal revenue generation alone. With a diverse portfolio of product candidates supported by robust R&D and a long cash runway facilitated through strategic deals, the company presents a measured approach to managing risk while pursuing advancements in cancer immunotherapy. The balanced focus on clinical stage progression alongside computational innovations underscores its multidisciplinary expertise and operational resilience.

Conclusion

In summary, Compugen stands as a significant player in the field of cancer immunotherapy by combining modern computational target discovery with strategic, collaborative drug development. Its innovative platform, diverse clinical pipeline, and robust partnerships place it in a unique position within the competitive landscape. Anchored by advanced AI/ML capabilities and a commitment to addressing unmet clinical needs, Compugen continues to set the stage for transformative advancements in the treatment of cancer.

Rhea-AI Summary

Compugen (NASDAQ: CGEN) reported Q3 2024 financial results and corporate updates. The company presented clinical data for COM701 at SITC 2024, showing durable responses in immunotherapy-resistant tumors. Plans include initiating an adaptive platform trial for COM701 in Q2 2025 for ovarian cancer patients. The company reported $17.1 million in revenues and a net profit of $1.3 million for Q3 2024. Cash position stands at $113.2 million, expected to fund operations into 2027. Partner AstraZeneca advanced rilvegostomig into additional Phase 3 trials, while COM503's Phase 1 trial is set to begin in Q4 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.05%
Tags
-
Rhea-AI Summary

Compugen (Nasdaq: CGEN) announced its participation in the Stifel 2024 Healthcare Conference in New York City. The company's management will engage in a fireside chat scheduled for Monday, November 18, 2024, at 8:35 am ET. The event will be accessible through a live webcast on the Investor Relations section of Compugen's website, with a replay available after the event. Compugen, operating as a clinical-stage cancer immunotherapy company, is known for its pioneering work in computational target discovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
conferences
-
Rhea-AI Summary

Compugen (CGEN) has announced promising data on the triple combination of COM701, COM902, and pembrolizumab in treating platinum-resistant ovarian cancer patients. The data will be presented at the SITC 2024 conference in Houston, Texas. The study showed a 17.4% confirmed objective response rate and a 43.5% disease control rate in 23 evaluable patients.

The treatment demonstrated a favorable safety profile with mostly Grade 2 or lower adverse events, and only one Grade 3 event reported. Dr. Oladapo Yeku from Harvard Medical School highlighted the treatment's durability and effectiveness in late-stage ovarian cancer patients. The company plans to advance COM701 to earlier stages of ovarian cancer therapy, particularly targeting patients who are ineligible for maintenance treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
conferences
Rhea-AI Summary

Daiichi Sankyo and AstraZeneca have initiated three global Phase 3 trials evaluating datopotamab deruxtecan (Dato-DXd) combinations in advanced nonsquamous non-small cell lung cancer (NSCLC). The trials include: TROPION-Lung10 testing Dato-DXd plus rilvegostomig in high PD-L1 expression patients; TROPION-Lung14 evaluating Dato-DXd plus osimertinib in EGFR mutated NSCLC; and TROPION-Lung15 studying Dato-DXd with/without osimertinib in EGFR mutated NSCLC that progressed on osimertinib. These trials are part of the expanding TROPION program, which now includes seven Phase 3 trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
-
Rhea-AI Summary

Compugen (Nasdaq: CGEN) announced it will release its Q3 2024 financial results on Tuesday, November 12, 2024, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM ET to discuss financial results and provide a corporate update. Management will also discuss data presented at the Society for Immunotherapy of Cancer Annual Meeting (November 8-10, 2024). The conference call will be accessible via phone and live webcast through Compugen's website, with a replay available afterward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
-
Rhea-AI Summary

Compugen (Nasdaq: CGEN) has announced that new clinical data will be presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, Texas, from November 8-10, 2024. The presentation will focus on the anti-tumor activity and safety of a triple combination therapy involving COM701, COM902, and pembrolizumab in heavily pre-treated patients with platinum-resistant ovarian cancer.

The poster presentation, titled "Triple blockade of DNAM-1axis with COM701 (anti-PVRIG) + COM902 (anti-TIGIT) + pembrolizumab shows preliminary antitumor activity in patients with platinum resistant ovarian cancer, interim results of Phase I trial," will be delivered by Dr. Oladapo Yeku, a Medical Oncologist from Massachusetts General Hospital, on Friday, November 8, 2024. The abstract number for this presentation is 985.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
conferences clinical trial
Rhea-AI Summary

Compugen (Nasdaq: CGEN) will present at the Single Cell Genomics 2024 conference in Greece from September 16-18, 2024. Dr. Roy Granit, Head of Computational Discovery, will showcase a poster on applying AI to gain insights into the novel immune checkpoint PVRIG through single-cell and spatial transcriptomics.

The presentation highlights additional biological insights generated using Compugen's AI/ML-powered computational discovery platform, UnigenTM. These findings support the potential of PVRIG inhibition to induce anti-tumor activity in indications previously resistant to immunotherapy, differentiating it from other immune checkpoints.

The poster presentation, titled 'Applying AI to Gain Insights into the Novel Immune Checkpoint PVRIG Through Single-Cell and Spatial Transcriptomics,' is scheduled for Monday, September 16, 2024. It will be available on Compugen's website following the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.2%
Tags
conferences
-
Rhea-AI Summary

Compugen (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, announced its upcoming virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available on-demand starting September 9, 2024, at 7:00 AM ET for 30 days on the company's Investor Relations website.

Compugen, known for its pioneering work in computational target discovery, aims to showcase its latest developments and strategies to investors and industry professionals. This presentation offers an opportunity for stakeholders to gain insights into Compugen's progress in the competitive field of cancer immunotherapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.42%
Tags
conferences
-
Rhea-AI Summary

Compugen (CGEN) reported Q2 2024 results, highlighting key achievements and financial updates:

1. FDA clearance of COM503 IND triggered a $30 million milestone payment from Gilead.

2. On track to present data from COM701 + COM902 + pembrolizumab study in platinum-resistant ovarian cancer in Q4 2024.

3. AstraZeneca provided a non-risk adjusted peak year revenue target of over $5 billion for rilvegostomig, with Compugen eligible for future milestones and royalties.

4. Q2 2024 revenues: $6.7 million, compared to no revenues in Q2 2023.

5. Cash position: $92.3 million as of June 30, 2024, with runway expected to fund operations into 2027.

6. Net loss: $2.1 million ($0.02 per share) in Q2 2024, compared to $9.3 million ($0.11 per share) in Q2 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
Rhea-AI Summary

Compugen (Nasdaq: CGEN) has received FDA clearance for its investigational new drug (IND) application for COM503, a potential first-in-class, high-affinity anti-IL-18 binding protein antibody for the treatment of solid tumors. This clearance triggers a $30 million milestone payment from Gilead Sciences, Inc., Compugen's licensing partner. The company is on track to initiate a Phase 1 trial for COM503 in Q4 2024.

COM503 represents a differentiated antibody approach to harness cytokine biology for cancer therapeutics, both as monotherapy and in combination treatments. This achievement strengthens Compugen's balance sheet, extending its expected cash runway into 2027. The company's preparation for the Phase 1 trial is well-advanced, showcasing its execution capabilities and diverse pipeline developed through its computational discovery engine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.39%
Tags

FAQ

What is the current stock price of Compugen (CGEN)?

The current stock price of Compugen (CGEN) is $1.31 as of April 4, 2025.

What is the market cap of Compugen (CGEN)?

The market cap of Compugen (CGEN) is approximately 132.3M.

What is Compugen's core business?

Compugen is a clinical-stage cancer immunotherapy company that focuses on discovering and developing novel drug targets using its proprietary computational discovery platform, Unigen™.

How does Compugen use computational methods in its drug discovery?

The company employs advanced AI and machine learning algorithms to simulate biological mechanisms and identify promising targets for therapeutic proteins and monoclonal antibodies, accelerating the discovery process.

Which therapeutic areas does Compugen focus on?

Compugen primarily targets unmet needs in immunology and oncology, developing treatments to enhance anti-tumor immune responses in various solid tumors.

What are some key product candidates in Compugen's pipeline?

Key candidates include COM701, a potential anti-PVRIG antibody; COM902, a potential anti-TIGIT antibody; and COM503 (GS-0321), a potential antibody that targets the IL-18 binding protein.

Who are Compugen's strategic partners?

Compugen has established collaborations with major pharmaceutical companies such as AstraZeneca and Gilead, which help advance its clinical trials and development initiatives while providing milestone payments and revenue sharing.

What role does the Unigen™ platform play at Compugen?

Unigen™ is the company’s AI/ML-powered computational discovery engine that integrates multi-omics data to identify novel drug targets, streamline candidate selection, and support clinical development in cancer immunotherapy.

How does Compugen's approach differ from traditional drug discovery?

By utilizing computational predictions and machine learning, Compugen accelerates candidate identification and validation, reducing the time and resources needed compared to conventional experimental methods.

What benefits do investors see in Compugen’s business model?

Investors may appreciate Compugen's diversified pipeline, strategic collaborations for milestone and royalty payments, and its integration of cutting-edge computational technologies which offset risks associated with early-stage clinical development.

How does Compugen address unmet needs in cancer treatment?

The company focuses on novel mechanisms of immune modulation through its unique product candidates, targeting specific pathways that inhibit effective anti-tumor immune responses, thus offering potential new treatment options for patients.

Where is Compugen headquartered?

Compugen is headquartered in Israel and also maintains offices in San Francisco, serving as a vital nexus for its global research and development activities.
Compugen

Nasdaq:CGEN

CGEN Rankings

CGEN Stock Data

132.32M
91.62M
2.03%
14.32%
1.77%
Biotechnology
Healthcare
Link
Israel
Holon